US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioArctic announces research collaboration with Eisai regarding BAN2401

Stockholm, Sweden, December 17, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new research collaboration is intended to further characterize the unique binding profile of BAN2401. “We welcome the opportunity to join forces with Eisai in this initiative to generate additional knowledge

BioArctic announces additional BAN2401 Phase 2b study results in early Alzheimer’s disease presented by Eisai at the 2018 CTAD conference

Stockholm, Sweden, October 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical Phase 2b study with BAN2401 in 856 patients with early Alzheimer’s disease (AD). BAN2401 is a selective anti-amyloid beta (Aβ) protofibril antibody. Statistically significant benefits were observed on the key efficacy endpoints at 18 months on slowing progression in Alzheimer’s Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured by using amyloid-PET (Positron Emission Tomography)

BioArctic signs a research agreement with Brain Biomarker Solutions in Gothenburg AB to develop new diagnostics for Alzheimer’s disease

Stockholm, Sweden, September 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has signed a research agreement with Brain Biomarker Solutions in Gothenburg AB (BBS). BBS was founded by the internationally well-known researchers in the area of Alzheimer diagnostics, Professors Kaj Blennow and Henrik Zetterberg and University of Gothenburg in Sweden. The objective of the research collaboration is to develop new and improved diagnostic methods for Alzheimer’s disease by identifying and measuring new biomarkers in cerebrospinal fluid (CSF) and blood. The goal is to be able to better

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media